Personalized Therapies in Inflammatory Complex Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-20

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564

Chronic Graft-versus-host-disease

RECRUITING PHASE2

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

NCT00307593

Wegener's Granulomatosis Churg-Strauss Syndrome Microscopic Polyangiitis

COMPLETED NA

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

NCT06413511

Autoimmune Diseases

WITHDRAWN PHASE1

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542

Chronic Graft-versus-host-disease

ACTIVE_NOT_RECRUITING PHASE3

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

NCT06263478

Chronic Graft-versus-host-disease

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase IIb study. The main objective of this study is to evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway.

Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®, Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using molecular analysis and decision making procedure by the Scientific committee.

For each patient, one targeted treatment will be administered according to the SmPC procedure for a treatment period of 6 months.

Primary efficacy endpoint:

Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters:

* 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10 mm),
* and/or 50% improvement of cutaneous activity assessed by the involved skin surface area,
* and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin).

An independent adjudication committee blinded to the treatment received, will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response.

Other secondary criteria will be assessed. Overall, this study will require a molecular analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance of targeted treatments chosen in a personalized analysis when classification is impossible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Disease Autoimmune Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (men or women) aged 18 years old and over
* Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract, eye, nerves and brain tissues, respiratory tract, cardio-vascular disorders, genito-urinary tract including kidney, musculo-skeletal tissues. Skin involvement is mandatory in order to be able to compare involved and non-involved tissue
* Signed informed consent

The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert committee meeting.

The disease alters significantly quality of life. The impairment of quality of life will be assessed based on the investigator's assessment.

The disease has been resistant to at least two prior lines of treatment \[for example : Hydroxychloroquine, Chloroquine, Colchicine, Methotrexate, Ciclosporine, Azathioprine, Mycophenolate mofetil, Disulone, Corticosteroids (prednisone, prednisolone, dexamethasone, methylprednisolone…)\].

Exclusion Criteria

* Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy
* Patients refusing biopsies
* Pregnancy
* Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method
* Breastfeeding
* Patients presenting disease needing urgent therapeutic measures
* Patients without health insurance or social security
* Participation in another interventional trial
* Patients under legal protection
* Patients unable to respect the wash out delay of previously taken medications before biopsy and before treatment initiation :

* Hydroxychloroquine (wash out period = 30 days)
* Chloroquine (wash out period = 7 days)
* Colchicine (wash out period = 7 days)
* Methotrexate (wash out period = 7 days)
* Ciclosporine (wash out period = 14 days)
* Azathioprine (wash out period = 14 days)
* Mycophenolate mofetil (wash out period = 14 days)
* Disulone (wash out period = 7 days)
* Corticosteroids (=prednisone, prednisolone, dexamethasone, methylprednisolone) (wash out period = 7 days for doses greater than 5mg)
* Patients with contra-indications to treatments : Severe or active infections including tuberculosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No